PURPOSE: The proportional reporting ratio (PRR) is the proportion of spontaneous reports for a given drug that are linked to a specific adverse outcome, divided by the corresponding proportion for all or several other drugs. The PRR is similar to the proportional mortality ratio (PMR), an old epidemiologic measure calculated from death registries and constructed in similar fashion to the PRR. The PMR has important deficiencies, however, which the PRR shares. Miettinen and Wang demonstrated that the PMR could be improved by reformulating it as an odds ratio and applying the principles of a case-control study to the measure. In this paper, we review the problem with the PRR and show how the corresponding odds ratio represents an improvement over the PRR. METHODS: The method used is discussion and illustration by way of a hypothetical example. RESULTS: The PRR does not estimate relative risk. If, however, a spontaneous report database is viewed as source data for a case-control study, the reporting odds ratio (ROR) can be used to estimate relative risk. Treating the data as source data for a case-control study allows for further reduction of bias by the judicious choice of controls. CONCLUSIONS: Calculating the ROR in spontaneous report databases offers advantages over the PRR. It allows for estimation of the relative risk, and focuses attention on which people or reports should be included or excluded from the control series, permitting more deliberate elimination of biases. It also highlights the inherent weaknesses in spontaneous report data, which become more evident in light of the usual principles of control selection in case-control studies.
PURPOSE: The proportional reporting ratio (PRR) is the proportion of spontaneous reports for a given drug that are linked to a specific adverse outcome, divided by the corresponding proportion for all or several other drugs. The PRR is similar to the proportional mortality ratio (PMR), an old epidemiologic measure calculated from death registries and constructed in similar fashion to the PRR. The PMR has important deficiencies, however, which the PRR shares. Miettinen and Wang demonstrated that the PMR could be improved by reformulating it as an odds ratio and applying the principles of a case-control study to the measure. In this paper, we review the problem with the PRR and show how the corresponding odds ratio represents an improvement over the PRR. METHODS: The method used is discussion and illustration by way of a hypothetical example. RESULTS: The PRR does not estimate relative risk. If, however, a spontaneous report database is viewed as source data for a case-control study, the reporting odds ratio (ROR) can be used to estimate relative risk. Treating the data as source data for a case-control study allows for further reduction of bias by the judicious choice of controls. CONCLUSIONS: Calculating the ROR in spontaneous report databases offers advantages over the PRR. It allows for estimation of the relative risk, and focuses attention on which people or reports should be included or excluded from the control series, permitting more deliberate elimination of biases. It also highlights the inherent weaknesses in spontaneous report data, which become more evident in light of the usual principles of control selection in case-control studies.
Authors: Miguel-Angel Maciá-Martínez; Francisco J de Abajo; Gilly Roberts; Jim Slattery; Bharat Thakrar; Antoni F Z Wisniewski Journal: Drug Saf Date: 2016-01 Impact factor: 5.606
Authors: Carmen Ferrajolo; Annalisa Capuano; Katia M C Verhamme; Martijn Schuemie; Francesco Rossi; Bruno H Stricker; Miriam C J M Sturkenboom Journal: Br J Clin Pharmacol Date: 2010-11 Impact factor: 4.335
Authors: June Almenoff; Joseph M Tonning; A Lawrence Gould; Ana Szarfman; Manfred Hauben; Rita Ouellet-Hellstrom; Robert Ball; Ken Hornbuckle; Louisa Walsh; Chuen Yee; Susan T Sacks; Nancy Yuen; Vaishali Patadia; Michael Blum; Mike Johnston; Charles Gerrits; Harry Seifert; Karol Lacroix Journal: Drug Saf Date: 2005 Impact factor: 5.606
Authors: Alfonso Carvajal; Diego Macias; Angélica Gutiérrez; Sara Ortega; María Sáinz; Luis H Martín Arias; Alfonso Velasco Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Rohit P Ojha; Bradford E Jackson; Joseph E Tota; Tabatha N Offutt-Powell; Karan P Singh; Sejong Bae Journal: Hum Vaccin Immunother Date: 2013-09-06 Impact factor: 3.452
Authors: Virginie Grouthier; Benedicte Lebrun-Vignes; Andrew M Glazer; Philippe Touraine; Christian Funck-Brentano; Antoine Pariente; Carine Courtillot; Anne Bachelot; Dan M Roden; Javid J Moslehi; Joe-Elie Salem Journal: Heart Date: 2018-05-02 Impact factor: 5.994